4//SEC Filing
Spellman David A 4
Accession 0001562180-22-002160
CIK 0001517022other
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 9:09 PM ET
Size
14.6 KB
Accession
0001562180-22-002160
Insider Transaction Report
Form 4
Spellman David A
SVP, CFO and Treasurer
Transactions
- Sale
Common Stock
2022-02-28$2.15/sh−7,400$15,946→ 69,402 total - Sale
Common Stock
2022-03-01$2.17/sh−803$1,743→ 128,599 total - Award
Common Stock
2022-02-28+60,000→ 129,402 total - Award
Employee Stock Option (Right to buy)
2022-02-28+225,000→ 225,000 totalExercise: $2.16Exp: 2032-02-28→ Common Stock (225,000 underlying)
Footnotes (4)
- [F1]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.
- [F2]The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
- [F3]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.
- [F4]The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.
Issuer
Akebia Therapeutics, Inc.
CIK 0001517022
Entity typeother
Related Parties
1- filerCIK 0001733204
Filing Metadata
- Form type
- 4
- Filed
- Mar 1, 7:00 PM ET
- Accepted
- Mar 2, 9:09 PM ET
- Size
- 14.6 KB